SuperworthNextCure market cap NXTC
Share price times shares outstanding: what the whole company sells for, since 2019.
- Today, Oct 23, 2026
- $22.8M
- Highest close in our data
- $1.9B
- Nov 2019
NextCure is worth $22.8M at the close on Oct 23, 2026, at $4.98 a share.
That is down 7% over the last year and down 90% over five years.
Its highest close in our data was $1.9B in Nov 2019.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $22.8M | $6M | $45.1M | −33% |
| 2025 | $34.2M | $8.1M | $37.8M | +49% |
| 2024 | $23M | $23M | $62.2M | −28% |
| 2023 | $31.8M | $29.6M | $50.4M | −19% |
| 2022 | $39.2M | $34.2M | $156.9M | −76% |
| 2021 | $165.8M | $158M | $374.7M | −45% |
| 2020 | $300.3M | $229.2M | $1.3B | −78% |
| 2019 | $1.3B | $332.1M | $1.9B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest NextCure's size, closest first, today.
| Company | Market cap |
|---|---|
| NXTCNextCure | $22.8M |
| ATNMActinium Pharmaceuticals | $47.8M |
| SPROSpero Therapeutics | $64.6M |
| LFVNLifevantage | $73.4M |
| NATRNatures Sunshine Products | $213.8M |
| Peer median | $69M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on NextCure
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.